Biotechnology company using computational biology to discover and develop new treatments for cancer and immunological diseases.
Immuneering Corporation, a biopharmaceutical firm headquartered in Cambridge, Massachusetts, specializes in advancing product candidates primarily within oncology and neuroscience. The company's robust pipeline is anchored by its lead product, IMM-1-104, a dual-MEK inhibitor tailored to address cancers such as pancreatic, melanoma, colorectal, and non-small cell lung cancer, specifically those driven by mutations in RAS and/or RAF genes. Complementing this, IMM-6-415 represents another promising candidate aimed at treating solid tumors.
Beyond its lead candidates, Immuneering Corporation is actively engaged in the discovery phase of five oncology programs. These initiatives are strategically designed to target crucial components of the MAPK (Mitogen-Activated Protein Kinase) and mTOR (Mechanistic Target of Rapamycin) pathways, pivotal in cancer cell signaling and growth. Additionally, the company is pursuing two discovery-stage neuroscience programs, underscoring its commitment to addressing unmet medical needs in both cancer and neurological disorders.
Founded in 2008, Immuneering Corporation has cultivated a strong foundation in Cambridge's thriving biotechnology community. Originally established as a subsidiary of Teva Pharmaceutical Industries Limited, the company has since evolved into an independent entity focused on leveraging its expertise in bioinformatics and computational biology to drive innovative drug development efforts.
Immuneering Corporation's location in Cambridge, a renowned hub for biomedical research and innovation, provides strategic advantages for collaboration and access to top-tier talent. With a dedicated focus on translating cutting-edge scientific discoveries into tangible therapies, the company is poised to make significant strides in advancing the future of cancer and neuroscience treatments.